日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Prolyl hydroxylase inhibitor desidustat improves stroke outcomes via enhancing efferocytosis in mice with chronic kidney disease.

脯氨酰羟化酶抑制剂地西达司他通过增强慢性肾病小鼠的胞吞作用来改善中风预后

Kaur Harpreet, Pandey Nilesh, Chandaluri Lakshmi, Shaaban Nirvana, Martinez Alexa, Kidder Evan, Patel Vishal J, Kshirsagar Samadhan G, Kumar Dhananjay, Frausto Louise, Pandit Rajan, Richard Koral S E, Anand Sumit Kumar, Das Sandeep, Vikram Ajit, Magdy Tarek, Lu Xiao-Hong, Orr A Wayne, Patel Harilal, Trivedi Ravi Kumar, Kansagra Kevinkumar, Joharapurkar Amit A, Parmar Deven V, Jain Mukul R, Rom Oren, Yurdagul Arif Jr, Dhanesha Nirav

Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants

一项随机、三臂、IV期临床试验中,同时接种伤寒VI结合疫苗与麻疹和风疹疫苗对健康婴儿的免疫原性和安全性结果

Rao, Songa Narayana; Ambike, Deepali; Patil, Mahantesh; Mankar, Sanjay Vasant; Verma, Nishant; Hanumante, Neeta; Sarangi, Lisa; Mitra, Monjori; Preeti, Godatwar; Deshmukh, Bhaskar Jedhe; Nanoti, Girish; Faridi, Mohammad Moonis Akbar; Daultani, Pavankumar; Mittal, Ravindra; Maithal, Kapil; Kansagra, Kevinkumar; Parmar, Deven V; Kunnathamman, Radhakrishnan; Elaiyaraja, Manickam; Dutta, Trayambak; Mahajan, Manish; Desai, Samir

An active post-marketing surveillance study to evaluate the safety and immunogenicity of Zyvac TCV in healthy participants

一项上市后监测研究,旨在评估Zyvac TCV在健康受试者中的安全性和免疫原性。

Mankar, Sanjay Vasant; Patel, Chintan; Chavan, Abhishek; Modi, Ravi; Sarangi, Lisa; Tripathi, Virendra Nath; Dash, Dillip Kumar; Narayan, Jai Prakash; Bandgar, Sunil; Kumar, N Ravi; Gill, Vinay Kumar; Kakkar, Munish Kumar; Mitra, Monjori; Daultani, Pavankumar; Mittal, Ravindra; Maithal, Kapil; Kansagra, Kevinkumar; Parmar, Deven V; Dutta, Trayambak; Mahajan, Manish; Desai, Samir

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

口服 NLRP3 炎症小体抑制剂 ZYIL1 的安全性、耐受性、药代动力学和药效学:首次人体 1 期研究(单次递增剂量和多次递增剂量)

Parmar, Deven V; Kansagra, Kevinkumar A; Momin, Taufik; Patel, Hardik B; Jansari, Gaurav A; Bhavsar, Jay; Shah, Chintan; Patel, Jayesh M; Ghoghari, Ashok; Barot, Ajay; Sharma, Bhavesh; Viswanathan, Kasinath; Patel, Harilal V; Jain, Mukul R